- cafead Oct 19, 2019 at 02:02: PM
via Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
- Thread starter cafead
- Start date
<
Similar threads